Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. biology: current status and future prospects. (B) OS by BMB. Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes. DLBCL can arise in virtually any part of the body and, depending on various f… Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites. Abraham Avigdor; Staging DLBCL: bone marrow biopsy or PET-CT?. doi: https://doi.org/10.1182/blood-2013-05-502575, In this issue of Blood, Khan and colleagues evaluated the clinical implications of marrow involvement identified by FDG–PET-CT (2-[18F]fluoro-2-deoxy-d-glucose–positron emission tomography combined with computed tomography) vs iliac crest biopsy in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL).

Efficacy of R‐GCVP in patients with late relapse of diffuse large B‐cell lymphoma. However, given the significant impact of BM histopathology on survival and outcome in DLBCL, as reported in this 1 and other studies, 5,6 the exclusion of BMB from staging procedures in DLBCL does not as yet appear justified in the context of clinical trials. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Patients having undergone immunomodulatory therapy may also be assessed by a modification of the Lugano criteria called LYRIC, which introduces the new category of "indeterminate response.". Lymphocytes are part of your immune system.They travel around your body in your lymphatic system, helping you fight infections.There are two types of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells). 2010;194 (1): W91-W103. Elledge SE. This site is intended for U.S. Journal of Experimental & Clinical Cancer Research. Cancer Research, 26, 1310. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). Hallmarks of cancer: the next generation. AJR Am J Roentgenol. Impact of salvage treatment modalities in patients with positive FDG‐PET/CT after R‐CHOP chemotherapy for aggressive B‐cell non‐Hodgkin lymphoma. Hopper KD, Diehl LF, Lesar M et-al. Overexpression of miR-222-3p Promotes the Proliferation and Inhibits the Apoptosis of Diffuse Large B-Cell Lymphoma Cells via Suppressing PPP2R2A. The management of primary mediastinal B‐cell lymphoma: a British Society for Haematology Good Practice Paper. This is called staging. Post-treatment surveillance imaging in lymphoma, http://www.bcshguidances.com/BCSH_PROCESS/42_EVIDENCE_LEVELS_AND_GRADES_OF_RECOMMENDATION.html, http://www.gradeworkinggroup.org/index.htm. Adapted from Figure 4 (panel A from 4B; panel B from 4D) in the article by Khan et al that begins on page 61. Detection of marrow involvement by either FDG–PET-CT scan or biopsy was, however, associated with different outcomes. The sensitivity and specificity for identifying marrow involvement were as high as 94% and 100% for PET-CT scan and only 40% and 100% for BMB, respectively. 4. Technology in Cancer Research & Treatment. T cells leave the bone marrow before they are completely matured, and finish maturing in the thymus gland.

Radiographics. Hanahan D, Weinberg D. This is an unprecedented time. Diffuse large B-cell lymphoma. 2008;111 (2): 504-16. This retrospective study provides valuable data on the power of FDG–PET-CT scanning in detecting focal BM involvement with DLBCL. Almost all lymphocytes begin growing in the bone marrow or lymph nodes. Diffuse large B cell lymphoma (DLBCL) is a cancer of B lymphocytes. Imaging in staging of malignant lymphoma: a systematic review. Many lymphoma staging systems for both Hodgkin lymphoma and non-Hodgkin lymphoma have been developed.. Search for other works by this author on: PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.

There are … Staging Diffuse Large B-Cell Lymphoma. Stage I or II.

Because of this, the authors were unable to demonstrate whether BM histology was an independent predictor of poor outcome, using a multivariate analysis.1. Residents only. PROFESSIONALS ONLY. In the light of these data, the role of BMB in DLBCL will probably be one of the major debatable issues in the upcoming workshops dealing with the new proposals to change staging criteria and response assessment for lymphoma.